Feuerstein G Z, Wang X, Barone F C
Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA.
Ann N Y Acad Sci. 1997 Oct 15;825:179-93. doi: 10.1111/j.1749-6632.1997.tb48428.x.
This review summarized evidence in support for the case that ischemia elicits an inflammatory condition in the injured brain. The inflammatory condition consists of cells (neutrophils at the onset and later monocytes) and mediators (cytokines, chemokines, others). It is clear that de novo upregulation of proinflammatory cytokines, chemokines and endothelial-leukocyte adhesion molecules in the brain follow soon after the ischemic insult and at a time when the cellular component is evolving. The significance of the inflammatory response to brain ischemia is not fully understood. Evidence is emerging in support of the possibility that the acute inflammatory reaction to brain ischemia may be causally related to brain damage. This evidence includes: 1) the capacity of cytokines to exacerbate brain damage; 2) the capacity of specific cytokine antagonists such as IL-1ra to reduce ischemic brain damage; 3) that depletion of circulating neutrophils reduces ischemic brain injury; 4) and that antagonists of the endothelial-leukocyte adhesion interactions (e.g., anti-ICAM-1) reduce ischemic brain injury. However, it should be kept in mind that cytokines were also argued to provide beneficial effects in brain injury as inferred from studies with TNF-receptor knock-out mice (p55 and p75 knock-out), which display increased sensitivity to brain ischemia, and the capacity of IL-1 to elicit the state of ischemic tolerance upon repeated administration. Nevertheless, the recent revelation on the capacity of ischemia to induce acute inflammation in the brain provides a new and fertile ground for new explorations for novel therapeutic agents that could confine the neuronal damage that follows ischemia. Furthermore, many of the genes that are upregulated by ischemia have growth-promotion capacity and therefore raise the possibility that such gene products may be useful in counteracting brain damage by enhancing repair and establishing compensatory mechanisms that enhance histological and functional recovery.
本综述总结了支持缺血在受损脑内引发炎症状态这一观点的证据。炎症状态由细胞(起始阶段的中性粒细胞及随后的单核细胞)和介质(细胞因子、趋化因子等)组成。很明显,缺血性损伤后不久,即在细胞成分演变的时期,脑内促炎细胞因子、趋化因子和内皮细胞 - 白细胞黏附分子会重新上调。脑缺血炎症反应的意义尚未完全明了。越来越多的证据支持脑缺血急性炎症反应可能与脑损伤存在因果关系这一可能性。这些证据包括:1)细胞因子加剧脑损伤的能力;2)特定细胞因子拮抗剂(如IL - 1ra)减轻缺血性脑损伤的能力;3)循环中性粒细胞的耗竭可减轻缺血性脑损伤;4)内皮细胞 - 白细胞黏附相互作用的拮抗剂(如抗ICAM - 1)减轻缺血性脑损伤。然而,应当记住,从TNF受体基因敲除小鼠(p55和p75基因敲除)的研究推断,细胞因子在脑损伤中也被认为具有有益作用,这些小鼠对脑缺血更敏感,以及重复给予IL - 1可诱导缺血耐受状态。尽管如此,最近关于缺血在脑内诱导急性炎症能力的揭示为探索新型治疗药物提供了新的、富有成果的领域,这些药物可限制缺血后随之而来的神经元损伤。此外,许多因缺血而上调的基因具有促进生长的能力,因此增加了这样一种可能性,即此类基因产物可能通过增强修复和建立促进组织学和功能恢复的代偿机制来对抗脑损伤。